Arbovirus surveillance in pregnant women in north-central Nigeria, 2019-2022

- 2 Jerry Ogwuche^{1,a}, Charlotte Ajeong Chang^{2,a}, Olukemi Ige³, Atiene S. Sagay³, Beth Chaplin²
- 3 Makshwar L. Kahansim³, Michael Paul³, Michael Elujoba¹, Godwin Imade³, Georgenia
- 4 Kweashi¹, Yu-Ching Dai⁴, Szu-Chia Hsieh⁴, Wei-Kung Wang⁴, Donald J. Hamel², Phyllis J.
- 5 Kanki²
- $6⁻¹$ Our Lady of Apostles Hospital, Jos, Nigeria;
- ² Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public
- Health, Boston, Massachusetts, USA;
- 9 ³ Jos University Teaching Hospital, University of Jos, Jos, Nigeria;
- ⁴ Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns
- School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA
- **Correspondence:** Phyllis J. Kanki (pkanki@hsph.harvard.edu)
- 13 ^a These authors contributed equally.

Abstract

- The adverse impact of Zika (ZIKV), dengue (DENV), and chikungunya (CHIKV) virus infection
- in pregnancy has been recognized in Latin America and Asia but is not well studied in Africa.
- In Nigeria, we screened 1006 pregnant women for ZIKV, DENV and CHIKV IgM/IgG by rapid
- test (2019-2022). Women with acute infection were recruited for prospective study and infants
- were examined for any abnormalities from delivery through six months. A subset of rapid test-
- reactive samples were confirmed using virus-specific ELISAs and neutralization assays.
- Prevalence of acute infection (IgM+) was 3.8%, 9.9% and 11.8% for ZIKV, DENV and CHIKV,
- respectively; co-infections represented 24.5% of all infections. Prevalence in asymptomatic
- women was twice the level of symptomatic infection. We found a significant association
- between acute maternal ZIKV/DENV/CHIKV infection and any gross abnormal birth outcome
- 25 ($p=0.014$).
- Further prospective studies will contribute to our understanding of the clinical significance of
- these endemic arboviruses in Africa.

Running Title

- ZIKV, DENV and CHIKV in pregnancy in Nigeria
-
- **Keywords:** Zika, dengue, chikungunya virus, arbovirus, pregnancy, microcephaly, West Africa, Nigeria
-

Introduction

 In recent times, the emergence and re-emergence of Zika (ZIKV), dengue (DENV), and chikungunya (CHIKV) viruses have caused significant outbreaks of human disease globally (*1, 2*). Genomic and phylogenetic studies have delineated the origins and evolution of these arboviruses, which each have multiple Asian or American strains and lineages that expanded from ancestral African strains (*3, 4*). Although originally discovered in sub-Saharan Africa, research on these viruses and their biology in people on the continent has been limited. Arbovirus outbreaks in Africa likely go unrecognized due to their non-specific clinical presentations shared with malaria and typhoid and the lack of diagnostic capabilities for surveillance. Across the globe, 90% of the estimated 200 million annual pregnancies occur in geographic regions with endemic or epidemic arboviruses (*5*). The 2015-2016 ZIKV outbreak in the Americas identified the teratogenic threat of ZIKV and renewed interest in the impact of other arboviruses on pregnancy and infant outcomes. Studies from outbreaks of ZIKV, DENV, and CHIKV have shown an increased risk of severe disease in pregnant women as well as fetal loss, prematurity, microcephaly and other birth defects or severe neonatal infection (*5*). While ZIKV, DENV and CHIKV infections may have similar clinical presentations, they exert temporally distinct impacts over the course of pregnancy. While antenatal ZIKV may result in

 microcephaly and congenital Zika syndrome (CZS), antenatal DENV is associated with preterm delivery and stillbirth, and CHIKV primarily impacts intra-partum outcomes resulting in neonatal disease and neurodevelopmental delays.

 Nigeria is the most populous country in Africa, with over 200 million inhabitants (*6*), it is large (357,000 square miles) with diverse terrains and climatic regions, and over 70% of the

 population lives in rural areas. Global environmental mapping studies suggest that in Africa, roughly 453 million people live in areas suitable for ZIKV transmission, of which 111 million live in Nigeria, the nation at highest risk on the continent (*7*). Previously, we reported that ZIKV has been circulating in West Africa for at least two decades (*8*). The seroprevalence of ZIKV IgM was 6.4% in Nigerian patients and phylogenetic analysis showed that the ZIKVs belonged to the African lineage. As noted by the WHO*,* a linkage between a ZIKV strain circulating in Africa and microcephaly or other complications would have a significant impact on global risk assessments (*9*). The ZIKV outbreak in the Americas raised the question of whether pre-existing cross-reactive immunity or herd immunity may have resulted in the lack of detection of ZIKV- induced microcephaly in Africa (*10*). In recent decades, DENV has emerged as a public health threat in Asia and Latin 68 America. Although this arbovirus has been described in Africa since the late $19th$ century and the *Aedes spp*. mosquito vector is ubiquitous, the epidemiology and public health importance in Africa is largely unknown (*11*). Although DENV outbreaks have been reported on the continent, diagnostics are lacking and febrile illnesses are frequently attributed to malaria. Halstead and others have considered genetic factors may be protective from disease based on the differential disease manifestations by race, as seen in outbreaks in Cuba (*12, 13*). Others have suggested that circulating endemic flaviviruses in Africa may provide cross-protection from severe dengue disease (*14*).

 The impact of DENV infection during pregnancy on birth outcomes has been reported largely in case reports and case series from Asia and the Americas (*5*). In a meta-analysis, symptomatic dengue disease in pregnant women was associated with an increased risk of

Study design and participants

 Pregnant women ≥18 years of age attending the antenatal clinics at Jos University Teaching Hospital and Our Lady of Apostles Hospital in Jos, north-central Nigeria were recruited for arbovirus screening from April 1, 2019 to January 31, 2022. Women presenting with any of six common Zika symptoms: fever ≥37.5**°**C, rash, headache, arthralgia, conjunctivitis, or myalgia were recruited for a screening questionnaire and rapid test for ZIKV, DENV and CHIKV. One asymptomatic woman was recruited for every four symptomatic women. All women provided written informed consent for the screening, and separate informed consent for participation with their infants in the prospective follow-up study. The study was approved by the institutional review boards of the Jos University Teaching Hospital and the Harvard T.H. Chan School of Public Health.

112 Participating women provided a finger prick sample for the DPP[®] ZCD IgM/IgG rapid test (ChemBio, Medford, NY). They were administered a questionnaire that collected information on participant demographics, clinical history, exposure, and symptoms and had a brief clinical examination. The rapid test result was provided to the women within 30 minutes 116 along with appropriate counseling. The DPP® ZCD IgM/IgG rapid test is CE-marked with 99- 100% sensitivity and specificity for each virus and antibody isotype. All ZIKV, DENV, or CHIKV rapid test IgM and IgM/IgG positive women (symptomatic or asymptomatic) were recruited for the observational prospective study. At all routine antenatal visits and through delivery, women were examined for symptoms and provided blood and urine samples, a subset of which were tested for IgM antibodies by ELISA, neutralization tests and for nucleic acid detection.

 At delivery, infants were examined for any abnormal clinical outcomes, including microcephaly and signs of congenital Zika syndrome. Any adverse pregnancy outcomes, including miscarriage, stillbirth, and premature delivery were also documented. Infants were followed at their routine follow-up visits: 6 weeks, 10 weeks, 14 weeks, and 6 months. They were observed for any developmental abnormalities, including ocular examinations. Microcephaly was defined as head circumference with Z-score less than or equal to -2 standard deviations (SD), calculated as the difference between the head circumference and the median head circumference of a reference population (same age and sex) divided by the SD for the reference population used by the WHO Multicentre Growth Reference Study (*26*). An infant was defined as low weight if their birth weight Z-score was less than -2 SD for their age and sex. An infant was defined as preterm if delivered earlier than 37 weeks gestational age, the Fenton growth charts were used to calculate Z-scores for head circumference and weight for preterm infants, as used at the hospitals (*27, 28*).

Confirmation of arbovirus serology

 Anti-ZIKV and anti-DENV IgM and IgG were determined by previously described ELISAs using DENV and ZIKV envelope protein fusion-loop (FL) mutated virus-like particles (VLP) as antigens, which greatly reduced cross-reactivities from other flaviviruses (*29*). The sensitivity/specificity of DENV FL-VLP-based IgM and IgG ELISAs were 75.0/95.8% and 100.0/93.0%, respectively; the sensitivity/specificity of ZIKV FL-VLP-based IgM and IgG ELISAs were 90.0/99.3% and 100.0/83.3%, respectively. Previously described ZIKV and DENV NS1 IgG ELISAs were also used to distinguish previous DENV and ZIKV infections (*30*).

163 Descriptive statistics of demographic and clinical data described the study population. The X² test was used in bivariate analyses to test for associations between demographic and exposure variables and arbovirus infection. Variables significant at p≤0.20 in bivariate analyses were included in the multivariate logistic regression model, and backwards elimination used to build

 the final model predicting acute arbovirus infection, which retained variables significant at p≤0.05.

Results

antenatal care visit, 478 at JUTH and 528 at OLA. One-third of women (312/1006, 31.0%)

showed antibody responses to one or more of the arboviruses, with 19.9% IgM or IgM/IgG

reactive and 11.1% reactive to IgG only (Figure 1). Acute or recent arbovirus prevalence,

defined by IgM or IgM/IgG seropositivity, was ZIKV 1.4% (14/1006), DENV 6.0% (60/1006)

and CHIKV 7.7% (77/1006), ZIKV+DENV 0.7% (7/1006), ZIKV+CHIKV 0.9% (9/1006),

DENV+CHIKV 2.5% (25/1006) and ZIKV+CHIKV+DENV 0.8% (8/1006) (Table 1).

 Acute infected women with IgM+ reactivity showed significant variation by arbovirus and time. Higher recruitment of symptomatic women corresponded to the three rainy seasons over the study period (Figure 2). To evaluate temporal trends, the study was divided into three time periods: April 2019-March 2020, April 2020-March 2021, and April 2021-January 2022. The IgM+ prevalence for any arbovirus was 26.7% (88/330) in the first time period and reduced

 to 16.0% (59/368) in period 2 and 17.2% (53/308) in period 3. Age-specific arbovirus prevalence demonstrated a characteristic pattern of endemic infection (Supplementary Figure S1).

 We analyzed baseline characteristics of pregnant women to identify risks for acute (IgM) arbovirus infection (Table 2). In bivariate analysis, OLA clinic, study year 2019-2020, age 25-34 years, Igbo/other ethnicity, and unemployment status were associated with acute infection. Questionnaire data on mosquito exposure also found that majority of daytime outdoors, travel to locales with mosquitoes, and mosquito bites during pregnancy were associated with acute arbovirus infection. In multiple logistic regression using clinic as a cluster variable, age 25-34 years, study year 2019-2020, unemployment status, majority outdoor day environment, travel to locales with mosquitoes, and prior mosquito bites (>2 weeks) remained statistically significant. Unexpectedly, lower rates of acute arbovirus infection were observed in women who reported symptoms at screening 132/787 (16.8%) compared to 68/219 (31.1%) in asymptomatic 202 women (Fishers exact p<0.001), ratio of asymptomatic to symptomatic of 2:1. We failed to observe high levels of IgG seroprevalence or hyper-endemic arbovirus infection in the absence of IgM, with relatively low levels of IgG reactivity to all three arboviruses (1.7-6.9%). We compared birth outcomes for 101 ZIKV/DENV/CHIKV rapid test IgM-positive women to 5930 JUTH and OLA delivery records from May 2019 to May 2021(Table 3). We 207 found potential associations between maternal ZIKV/DENV/CHIKV infection during pregnancy 208 and macerated stillbirth ($p=0.017$), asymmetric intrauterine growth retardation ($p=0.017$),

209 microcephaly ($p<0.001$), cleft lip/palate ($p=0.017$), polydactyly ($p=0.017$), and multiple

210 congenital anomalies ($p<0.001$) of the infant. We found a significant association between

 maternal ZIKV/DENV/CHIKV infection during pregnancy and any adverse or abnormal gross 212 birth outcome $(p=0.014)$.

Discussion

 Our surveillance study in pregnant women provides new insights into the epidemiology of arbovirus infection in a West African setting. Spanning three rainy seasons, our study detected regular peaks in symptomatic pregnant women enrollment coincident with rainy seasons and heightened risk for mosquito transmission. We described acute infection with ZIKV, DENV and CHIKV continuously throughout the 34-month study, which decreased during the COVID-19 pandemic, with an overall IgM prevalence of 3.8% ZIKV, 9.9% DENV, and 11.8% CHIKV. Geographic regions with endemic *Aedes sp*. may be at risk for co-circulation of ZIKV,

DENV and CHIKV, as well as other related and serologically cross-reactive viruses such as

 Yellow Fever virus (YFV), West Nile virus (WNV), Usutu virus and the alphavirus O'nyong- nyong virus. The similar non-distinguishing and transient clinical presentations and diagnostic assays compromised by cross-reactivity hinder disease surveillance efforts. Comprehensive arbovirus surveillance is rarely performed in most African settings where inadequate infrastructure and/or the cost of testing are prohibitive. As a result, most studies are cross- sectional surveys on febrile patients that focus on a single viral pathogen, limiting our understanding of arbovirus co-infection. We found significant ZIKV, DENV, and CHIKV co- infections in pregnant women comprising 24.5% of all IgM-positive infections. Co-infection with CHIKV and DENV (with or without ZIKV) represented 67.3% of the co-infections and 18.4% ZIKV-CHIKV. In Brazil and Colombia, pregnant women with multiple arbovirus infections have been described (*38, 39*). Case reports of congenital co-infection of CHIKV and ZIKV described increased disease manifestations often leading to miscarriage (*40*). The clinical significance of single versus multiple co-infections remains unclear. Although DENV, ZIKV and CHIKV have historical origins in Africa, severe arbovirus disease outbreaks have been only rarely described. For ZIKV, the rapid geographic dispersal and distinct disease manifestations in the 2015-16 epidemic in the Americas and the re-emergence in the 2015 Cape Verde and 2016 Guinea Bissau outbreaks on the African continent suggest that this may be changing (*9*). However, it is notable that these two outbreaks were associated with the ZIKV of Asian lineage. We have previously reported a 6% seroprevalence in febrile West Africans (2004-2016) with African lineage ZIKV (*8*), similar to the reported 6.2% IgM seroprevalence by ZIKV NS1-based ELISA in north-central Nigeria in 2018 (*41*). This low prevalence profile may be explained by the mosquito vectors; lower ZIKV transmission potential

restrictions which could not be explained by seasonal dengue cycles or underreporting (*43, 44*).

In our time period analysis, we also saw a reduction in acute IgM-positive arbovirus infections in

pregnant women from 26.7% in the first time period to 16.0% and 17.2% from 2020-2022,

coinciding with the COVID-19 pandemic. The Nigerian governmental response to the COVID-

19 pandemic began in March 2020, which closed national and state borders and instituted weeks

of stay-at-home orders, followed by restricted movement and curfews. Antenatal attendance

dropped by 50% for several months and COVID-19 surges along with other imposed public

health restrictions likely limited population movement and gathering.

 In the literature, most studies of ZIKV and DENV are based on hospital-based disease surveillance whereby patients presenting with fever or other significant flavivirus symptoms present to healthcare settings for care. By contrast, our study population consisted of healthy and mildly symptomatic pregnant women attending antenatal clinics (Supplementary Table S3). We found that the rate of acute arbovirus infection was two times higher in asymptomatic women (31.1%) compared with mildly symptomatic women (16.8%). Other arbovirus studies have reported that most infections are asymptomatic and symptoms non-specific, with the ratio of symptomatic to inapparent infection ranging from 1:1 to 1:19 with DENV and 1:0.03 to 1:1.2 with CHIKV (*45-48*). In the 2007 ZIKV outbreaks in Yap Island, household surveillance estimated a ratio of 1 symptomatic to every 4.4 asymptomatic infected individuals (*49, 50*).

 Endemic exposure in Africa and Asia may limit recognized outbreaks via herd immunity, which could be imparted by multiple cross-reacting flaviviruses.

 High arbovirus seroprevalence rates have been reported in serosurveys among febrile hospital outpatients in Nigeria. In a meta-analysis of CHIKV in Nigeria, 7 cross-sectional studies contributed to the pooled anti-CHIKV IgM prevalence of 26.7% and 29.3%; these studies were conducted in the North-east and South-west of the country, where geographic region was a predictor for high seroprevalence (*51*). In contrast, our study demonstrated lower rates of both acute IgM and convalescent/remote IgG seroreactivity throughout the study period, consistent with our previous studies (*8*). Differences in geographic region, health status of study participants and serologic assays employed may provide some explanation for the apparent differences in results from our study and previous studies in the country.

 Microcephaly in ZIKV infected infants in the 2015-16 outbreak of the Americas increased interest in the pathologic effects of these previously poorly studied flaviviruses. ZIKV, DENV and CHIKV have been associated with adverse pregnancy outcomes including miscarriage, stillbirths and perinatal death (*22, 52, 53*). In our study, microcephaly was found in 6/101 (5.9%) acute arbovirus-infected women compared to 32/5930 (0.5%) in the control 294 hospital deliveries, $(p<0.001)$. We were not able to confirm arbovirus transmission in all infants born to IgM+ mothers, so we are cautious in interpreting these results. Nonetheless, the significant differences in infants born to arbovirus-infected women compared to the community control population warrant future study. Acute arbovirus infection was significantly associated with adverse and gross abnormal birth outcomes in both rapid test and confirmed subset analysis (p=0.014 and 0.005, respectively). We also report significant associations with multiple 300 congenital anomalies ($p<0.001$), which should be studied further.

 Our study has several limitations. The low-level prevalence rates of individual arbovirus infections and high rates of co-infections made direct associations with maternal and infant outcomes difficult. We were not able to confirm all rapid test IgM/IgG samples with other confirmatory assays. As our study population was pregnant women, some arbovirus symptoms are conflated with common pregnancy symptoms. The prospective study design and evaluation of multiple arboviruses was a strength of our study. We were able to describe acute and convalescent-phase arbovirus infection, frequent co-infection, and significant acute arbovirus 308 infection in asymptomatic pregnant women. Most importantly, with evaluation of $~6000$ deliveries at our study clinics we describe a significant association of birth abnormalities in pregnant women with acute arbovirus infection. Larger studies are needed to verify these associations and identify risk factors for infant abnormalities given arboviral infection/coinfection during pregnancy. ZIKV, DENV and CHIKV are arboviruses of global public health importance. While their dynamic epidemiology and association with clinical disease are actively studied in the Americas and Asia, the biological consequences of these endemic viruses in Africa remain poorly understood. Our study demonstrated low-level but persistent risk and exposure of all three viruses in pregnant women in Nigeria. The significant rates of asymptomatic infection and potential association with abnormal birth outcomes warrant further epidemiologic research to reveal the burden of disease, risks of transmission, and immunopathogenesis linked to disease outcomes of these viruses on the continent.

Declaration of interests

We declare no competing interests.

Acknowledgments

- We acknowledge the invaluable support of our clinic and laboratory staff at JUTH and OLA that
- enabled this study.

Role of the funding source

Research reported in this publication was supported by the National Institutes of Health under

award number R21AI137840 (Kanki) and R01AI149502 (Wang). The content is solely the

responsibility of the authors and does not necessarily represent the official views of the National

Institutes of Health.

References

 1. Wilder-Smith A, Gubler DJ, Weaver SC, Monath TP, Heymann DL, Scott TW. Epidemic arboviral diseases: priorities for research and public health. Lancet Infect Dis. 2017;17(3):e101- e6. doi: 10.1016/S1473-3099(16)30518-7. PubMed PMID: 28011234.

 2. Musso D, Rodriguez-Morales AJ, Levi JE, Cao-Lormeau VM, Gubler DJ. Unexpected outbreaks of arbovirus infections: lessons learned from the Pacific and tropical America. Lancet Infect Dis. 2018;18(11):e355-e61. doi: 10.1016/S1473-3099(18)30269-X. PubMed PMID: 29934112.

 3. Aliota MT, Bassit L, Bradrick SS, Cox B, Garcia-Blanco MA, Gavegnano C, et al. Zika in the Americas, year 2: What have we learned? What gaps remain? A report from the Global Virus Network. Antiviral Res. 2017;144:223-46. doi: 10.1016/j.antiviral.2017.06.001. PubMed PMID: 28595824; PubMed Central PMCID: PMC5920658.

 4. Lanciotti RS, Lambert AJ. Phylogenetic Analysis of Chikungunya Virus Strains Circulating in the Western Hemisphere. Am J Trop Med Hyg. 2016;94(4):800-3. doi: 10.4269/ajtmh.15-0375. PubMed PMID: 26856917; PubMed Central PMCID: PMC4824221.

 5. Charlier C, Beaudoin MC, Couderc T, Lortholary O, Lecuit M. Arboviruses and pregnancy: maternal, fetal, and neonatal effects. Lancet Child Adolesc Health. 2017;1(2):134-46. doi: 10.1016/S2352-4642(17)30021-4. PubMed PMID: 30169203.

 6. WorldBank. Nigeria Data 2016 [20 June 2016]. Available from: [http://data.worldbank.org/country/nigeria.](http://data.worldbank.org/country/nigeria)

 7. Messina JP, Kraemer MU, Brady OJ, Pigott DM, Shearer FM, Weiss DJ, et al. Mapping global environmental suitability for Zika virus. Elife. 2016;5. Epub 2016/04/20. doi: 10.7554/eLife.15272. PubMed PMID: 27090089; PubMed Central PMCID: 4889326.

 8. Herrera BB, Chang CA, Hamel DJ, Mboup S, Ndiaye D, Imade G, et al. Continued Transmission of Zika Virus in Humans in West Africa, 1992-2016. J Infect Dis. 2017;215(10):1546-50. Epub 2017/04/12. doi: 10.1093/infdis/jix182. PubMed PMID: 28398562; PubMed Central PMCID: PMC5853591.

 9. WHO. Zika situation report. Zika virus microcephaly Guillain-Barré syndrome [cited 2017 June 3, 2017]. Available from: [http://www.who.int/emergencies/zika-virus/situation-](http://www.who.int/emergencies/zika-virus/situation-report/10-march-2017/en/)[report/10-march-2017/en/.](http://www.who.int/emergencies/zika-virus/situation-report/10-march-2017/en/)

 10. Weaver SC, Costa F, Garcia-Blanco MA, Ko AI, Ribeiro GS, Saade G, et al. Zika virus: History, emergence, biology, and prospects for control. Antiviral Res. 2016;130:69-80. doi: 10.1016/j.antiviral.2016.03.010. PubMed PMID: 26996139; PubMed Central PMCID: PMC4851879.

 11. Amarasinghe A, Kuritsk JN, Letson GW, Margolis HS. Dengue virus infection in Africa. Emerg Infect Dis. 2011;17(8):1349-54. doi: 10.3201/eid1708.101515. PubMed PMID: 21801609; PubMed Central PMCID: PMC3381573.

 12. Bravo JR, Guzman MG, Kouri GP. Why dengue haemorrhagic fever in Cuba? 1. Individual risk factors for dengue haemorrhagic fever/dengue shock syndrome (DHF/DSS). Transactions of the Royal Society of Tropical Medicine and Hygiene. 1987;81(5):816-20. doi: 10.1016/0035- 9203(87)90041-1. PubMed PMID: 3450004.

 13. Garcia G, Sierra B, Perez AB, Aguirre E, Rosado I, Gonzalez N, et al. Asymptomatic dengue infection in a Cuban population confirms the protective role of the RR variant of the FcgammaRIIa polymorphism. Am J Trop Med Hyg. 2010;82(6):1153-6. doi: 10.4269/ajtmh.2010.09-0353. PubMed PMID: 20519616; PubMed Central PMCID: PMC2877427.

 14. Gubler DJ. The changing epidemiology of yellow fever and dengue, 1900 to 2003: full circle? Comparative immunology, microbiology and infectious diseases. 2004;27(5):319-30. doi: 10.1016/j.cimid.2004.03.013. PubMed PMID: 15225982.

 15. Paixao ES, Teixeira MG, Costa M, Rodrigues LC. Dengue during pregnancy and adverse fetal outcomes: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16(7):857-65. doi: 10.1016/S1473-3099(16)00088-8. PubMed PMID: 26949028.

 16. Vazeille M, Mousson L, Martin E, Failloux AB. Orally co-Infected Aedes albopictus from La Reunion Island, Indian Ocean, can deliver both dengue and chikungunya infectious viral particles in their saliva. PLoS Negl Trop Dis. 2010;4(6):e706. Epub 2010/06/15. doi: 10.1371/journal.pntd.0000706. PubMed PMID: 20544013; PubMed Central PMCID: PMC2882319.

 17. Ruckert C, Weger-Lucarelli J, Garcia-Luna SM, Young MC, Byas AD, Murrieta RA, et al. Impact of simultaneous exposure to arboviruses on infection and transmission by Aedes aegypti mosquitoes. Nat Commun. 2017;8:15412. Epub 2017/05/20. doi: 10.1038/ncomms15412.

PubMed PMID: 28524874; PubMed Central PMCID: PMC5454532.

 18. Goertz GP, Vogels CBF, Geertsema C, Koenraadt CJM, Pijlman GP. Mosquito co- infection with Zika and chikungunya virus allows simultaneous transmission without affecting vector competence of Aedes aegypti. PLoS Negl Trop Dis. 2017;11(6):e0005654. Epub 2017/06/02. doi: 10.1371/journal.pntd.0005654. PubMed PMID: 28570693; PubMed Central PMCID: PMC5469501.

 19. Vogels CBF, Ruckert C, Cavany SM, Perkins TA, Ebel GD, Grubaugh ND. Arbovirus coinfection and co-transmission: A neglected public health concern? PLoS Biol. 2019;17(1):e3000130. Epub 20190122. doi: 10.1371/journal.pbio.3000130. PubMed PMID: 30668574; PubMed Central PMCID: PMC6358106.

 20. Waggoner JJ, Gresh L, Vargas MJ, Ballesteros G, Tellez Y, Soda KJ, et al. Viremia and Clinical Presentation in Nicaraguan Patients Infected With Zika Virus, Chikungunya Virus, and

 Dengue Virus. Clin Infect Dis. 2016;63(12):1584-90. Epub 20160830. doi: 10.1093/cid/ciw589. PubMed PMID: 27578819; PubMed Central PMCID: PMC5146717.

21. Borgherini G, Poubeau P, Staikowsky F, Lory M, Le Moullec N, Becquart JP, et al.

 Outbreak of chikungunya on Reunion Island: early clinical and laboratory features in 157 adult patients. Clin Infect Dis. 2007;44(11):1401-7. Epub 20070418. doi: 10.1086/517537. PubMed

PMID: 17479933.

22. Ramful D, Carbonnier M, Pasquet M, Bouhmani B, Ghazouani J, Noormahomed T, et al.

Mother-to-child transmission of Chikungunya virus infection. Pediatr Infect Dis J.

 2007;26(9):811-5. Epub 2007/08/28. doi: 10.1097/INF.0b013e3180616d4f. PubMed PMID: 17721376.

- 23. Touret Y, Randrianaivo H, Michault A, Schuffenecker I, Kauffmann E, Lenglet Y, et al. [Early maternal-fetal transmission of the Chikungunya virus]. Presse Med. 2006;35(11 Pt 1):1656- 8. Epub 2006/11/07. doi: 10.1016/S0755-4982(06)74874-6. PubMed PMID: 17086120.
- 24. Gerardin P, Barau G, Michault A, Bintner M, Randrianaivo H, Choker G, et al. Multidisciplinary prospective study of mother-to-child chikungunya virus infections on the island

 of La Reunion. PLoS Med. 2008;5(3):e60. doi: 10.1371/journal.pmed.0050060. PubMed PMID: 18351797; PubMed Central PMCID: PMC2267812.

25. Gerardin P, Samperiz S, Ramful D, Boumahni B, Bintner M, Alessandri JL, et al.

Neurocognitive outcome of children exposed to perinatal mother-to-child Chikungunya virus

infection: the CHIMERE cohort study on Reunion Island. PLoS Negl Trop Dis. 2014;8(7):e2996.

 Epub 2014/07/18. doi: 10.1371/journal.pntd.0002996. PubMed PMID: 25033077; PubMed Central PMCID: PMC4102444.

 26. WHO. WHO Child Growth Standards: World Health Organization; 2007 [cited 2017]. 426 Available from: [http://www.who.int/childgrowth/standards/second_set/technical_report_2.pdf.](http://www.who.int/childgrowth/standards/second_set/technical_report_2.pdf)

427 27. Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. BMC pediatrics. 2013;13:59. Epub 20130420. doi: 10.1186/1471-2431- 13-59. PubMed PMID: 23601190; PubMed Central PMCID: PMC3637477.

 28. Chou JH, Roumiantsev S, Singh R. PediTools Electronic Growth Chart Calculators: Applications in Clinical Care, Research, and Quality Improvement. J Med Internet Res. 2020;22(1):e16204. Epub 20200130. doi: 10.2196/16204. PubMed PMID: 32012066; PubMed Central PMCID: PMC7058170.

29. Tsai WY, Youn HH, Brites C, Tsai JJ, Tyson J, Pedroso C, et al. Distinguishing Secondary

Dengue Virus Infection From Zika Virus Infection With Previous Dengue by a Combination of 3

 Simple Serological Tests. Clin Infect Dis. 2017;65(11):1829-36. doi: 10.1093/cid/cix672. PubMed PMID: 29020159; PubMed Central PMCID: PMC5850648.

 30. Tsai WY, Driesse K, Tsai JJ, Hsieh SC, Sznajder Granat R, Jenkins O, et al. Enzyme-linked immunosorbent assays using virus-like particles containing mutations of conserved residues on envelope protein can distinguish three flavivirus infections. Emerg Microbes Infect. 2020;9(1):1722-32. Epub 2020/07/21. doi: 10.1080/22221751.2020.1797540. PubMed PMID: 32684139; PubMed Central PMCID: PMC7473235.

 31. Tsai WY, Chen HL, Tsai JJ, Dejnirattisai W, Jumnainsong A, Mongkolsapaya J, et al. Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine. J Virol. 2018;92(23). doi: 10.1128/JVI.00556-18. PubMed PMID: 30185598; PubMed Central PMCID: PMC6232466.

32. Control CfD. Guidance for US Laboratories Testing for Zika Virus Infection 2017.

Available from: [https://www.cdc.gov/zika/laboratories/lab-guidance.html.](https://www.cdc.gov/zika/laboratories/lab-guidance.html)

 33. Sagay SA, Hsieh S-C, Dai Y-C, Chang CA, Ogwuche J, Ige K, et al. Association of recent Chikungunya virus infection of pregnant women with intrauterine transmission and abnormal infant outcomes in Nigeria. submitted. 2023.

 34. Tsai JJ, Liu CK, Tsai WY, Liu LT, Tyson J, Tsai CY, et al. Seroprevalence of dengue virus in two districts of Kaohsiung City after the largest dengue outbreak in Taiwan since World War II. PLoS Negl Trop Dis. 2018;12(10):e0006879. Epub 2018/10/26. doi: 10.1371/journal.pntd.0006879. PubMed PMID: 30356316; PubMed Central PMCID: PMC6218099

 35. Tyson J, Tsai WY, Tsai JJ, Brites C, Massgard L, Ha Youn H, et al. Combination of Nonstructural Protein 1-Based Enzyme-Linked Immunosorbent Assays Can Detect and Distinguish Various Dengue Virus and Zika Virus Infections. J Clin Microbiol. 2019;57(2). doi: 10.1128/JCM.01464-18. PubMed PMID: 30429254; PubMed Central PMCID: PMC6355536.

 36. Houng HS, Chung-Ming Chen R, Vaughn DW, Kanesa-thasan N. Development of a fluorogenic RT-PCR system for quantitative identification of dengue virus serotypes 1-4 using conserved and serotype-specific 3' noncoding sequences. J Virol Methods. 2001;95(1-2):19-32. doi: 10.1016/s0166-0934(01)00280-4. PubMed PMID: 11377710.

 37. Waggoner JJ, Gresh L, Mohamed-Hadley A, Ballesteros G, Davila MJ, Tellez Y, et al. Single-Reaction Multiplex Reverse Transcription PCR for Detection of Zika, Chikungunya, and Dengue Viruses. Emerg Infect Dis. 2016;22(7):1295-7. Epub 20160715. doi: 10.3201/eid2207.160326. PubMed PMID: 27184629; PubMed Central PMCID: PMC4918162.

 38. Brasil P, Calvet GA, Siqueira AM, Wakimoto M, de Sequeira PC, Nobre A, et al. Zika Virus Outbreak in Rio de Janeiro, Brazil: Clinical Characterization, Epidemiological and Virological Aspects. PLoS Negl Trop Dis. 2016;10(4):e0004636. Epub 2016/04/14. doi: 10.1371/journal.pntd.0004636. PubMed PMID: 27070912; PubMed Central PMCID: PMC4829157.

 39. Villamil-Gomez WE, Rodriguez-Morales AJ, Uribe-Garcia AM, Gonzalez-Arismendy E, Castellanos JE, Calvo EP, et al. Zika, dengue, and chikungunya co-infection in a pregnant woman from Colombia. Int J Infect Dis. 2016;51:135-8. Epub 2016/10/26. doi: 10.1016/j.ijid.2016.07.017. PubMed PMID: 27497951.

 40. Barr KL, Vaidhyanathan V. Chikungunya in Infants and Children: Is Pathogenesis Increasing? Viruses. 2019;11(3). Epub 2019/03/27. doi: 10.3390/v11030294. PubMed PMID: 30909568; PubMed Central PMCID: PMC6466311.

 41. Mathe P, Egah DZ, Muller JA, Shehu NY, Obishakin ET, Shwe DD, et al. Low Zika virus seroprevalence among pregnant women in North Central Nigeria, 2016. J Clin Virol. 2018;105:35- 40. Epub 20180526. doi: 10.1016/j.jcv.2018.05.011. PubMed PMID: 29885620.

 42. Aubry F, Dabo S, Manet C, Filipovic I, Rose NH, Miot EF, et al. Enhanced Zika virus susceptibility of globally invasive Aedes aegypti populations. Science. 2020;370(6519):991-6. doi: 10.1126/science.abd3663. PubMed PMID: 33214283.

 43. Sasmono RT, Santoso MS. Movement dynamics: reduced dengue cases during the COVID-19 pandemic. Lancet Infect Dis. 2022;22(5):570-1. Epub 20220302. doi: 10.1016/S1473- 3099(22)00062-7. PubMed PMID: 35247322; PubMed Central PMCID: PMC8890753.

 44. Chen Y, Li N, Lourenco J, Wang L, Cazelles B, Dong L, et al. Measuring the effects of COVID-19-related disruption on dengue transmission in southeast Asia and Latin America: a statistical modelling study. Lancet Infect Dis. 2022;22(5):657-67. Epub 20220302. doi: 10.1016/S1473-3099(22)00025-1. PubMed PMID: 35247320; PubMed Central PMCID: PMC8890758.

 45. Montoya M, Gresh L, Mercado JC, Williams KL, Vargas MJ, Gutierrez G, et al. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl Trop Dis. 2013;7(8):e2357. doi: 10.1371/journal.pntd.0002357. PubMed PMID: 23951377; PubMed Central PMCID: PMC3738476.

 46. Endy TP, Anderson KB, Nisalak A, Yoon IK, Green S, Rothman AL, et al. Determinants of inapparent and symptomatic dengue infection in a prospective study of primary school children in Kamphaeng Phet, Thailand. PLoS Negl Trop Dis. 2011;5(3):e975. Epub 20110301. doi: 10.1371/journal.pntd.0000975. PubMed PMID: 21390158; PubMed Central PMCID: PMC3046956.

- 47. Bustos Carrillo F, Collado D, Sanchez N, Ojeda S, Lopez Mercado B, Burger-Calderon R, et al. Epidemiological Evidence for Lineage-Specific Differences in the Risk of Inapparent Chikungunya Virus Infection. J Virol. 2019;93(4). Epub 20190205. doi: 10.1128/JVI.01622-18. PubMed PMID: 30463967; PubMed Central PMCID: PMC6364014.
- 48. Bettis AA, L'Azou Jackson M, Yoon IK, Breugelmans JG, Goios A, Gubler DJ, et al. The global epidemiology of chikungunya from 1999 to 2020: A systematic literature review to inform 511 the development and introduction of vaccines. PLoS Negl Trop Dis. 2022;16(1):e0010069. Epub 20220112. doi: 10.1371/journal.pntd.0010069. PubMed PMID: 35020717; PubMed Central PMCID: PMC8789145.
- 49. Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL, Lanciotti RS, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med. 2009;360(24):2536-43. doi: 10.1056/NEJMoa0805715. PubMed PMID: 19516034.
- 50. Eppes C, Rac M, Dunn J, Versalovic J, Murray KO, Suter MA, et al. Testing for Zika virus infection in pregnancy: key concepts to deal with an emerging epidemic. American journal of obstetrics and gynecology. 2017;216(3):209-25. doi: 10.1016/j.ajog.2017.01.020. PubMed PMID: 28126366.
- 51. Abdullahi IN, Akande AO, Muhammed Y, Rogo LD, Oderinde BS. Prevalence Pattern of Chikungunya Virus Infection in Nigeria: A Four Decade Systematic Review and Meta-analysis. Pathog Glob Health. 2020;114(3):111-6. Epub 20200319. doi: 10.1080/20477724.2020.1743087. PubMed PMID: 32191166; PubMed Central PMCID: PMC7241486.
- 52. van der Eijk AA, van Genderen PJ, Verdijk RM, Reusken CB, Mogling R, van Kampen JJ, et al. Miscarriage Associated with Zika Virus Infection. N Engl J Med. 2016;375(10):1002-4. Epub 20160727. doi: 10.1056/NEJMc1605898. PubMed PMID: 27463941.
- 53. Arragain L, Dupont-Rouzeyrol M, O'Connor O, Sigur N, Grangeon JP, Huguon E, et al. Vertical Transmission of Dengue Virus in the Peripartum Period and Viral Kinetics in Newborns and Breast Milk: New Data. J Pediatric Infect Dis Soc. 2017;6(4):324-31. doi: 10.1093/jpids/piw058. PubMed PMID: 27760799.
-
-
-
-
-

- Figure 1: Venn diagram of acute (IgM) ZIKV, DENV and CHIKV infection
- Women with any IgM reactivity (200, 19.9%) by arbovirus.

- 551 Figure 2: Acute (IgM) arbovirus infection (2019-2022)
- 552 Seroprevalence (left axis) and number of women tested (right axis); rainy season indicated by 553 rain cloud.
	- Ω 10 20 30 40 50 60 70 80 0 10 20 30 Apr.19 **Vun-19** Aug-19 Oct-19 Dect¹⁹ Febr²⁰ Apr-20 **Jun-20** Aug-20 Oct-20 Dec-20 Feb²² Apr-21 Jun-21 Aug-21 Oct-22 Dec-21 CHKV DENV ZIKV --Total
- 554
- 555
- 556
- 557
-
- 558
- 559
- 560
- 561

564 *IgM, immunoglobulin M; IgG, immunoglobulin G; ZIKV, Zika virus; CHIKV, chikungunya virus; DENV, dengue virus.

564
565

566 Table 2. Baseline characteristics and risk factors for Zika, dengue, and chikungunya infection (Chembio IgM+) among pregnant
567 women in Jos, Nigeria, April 2019-January 2022* 567 women in Jos, Nigeria, April 2019-January 2022*

 \ddagger Site used as cluster variable in logistic regression analyses.

572

573

Table 3. Abnormal delivery outcomes among study infants born to mothers with any acute Zika, dengue, or chikungunya infection versus infants in birth registers at Jos University Teaching Hospital and Our Lady of Apostles Hospital, Jos, Nigeria, May 2019–May 2021* 574
575
576

577 *ZIKV, Zika virus; DENV, dengue virus; CHIKV, chikungunya virus; IgM, immunoglobulin M. 578 †Data shown includes adverse and gross abnormal outcomes recorded in hospital birth registers; other outcomes, such as neonatal sepsis and jaundice, are not shown. 101 study infants born to mothers with a Chembio IgM+ rapid test result during the time period were observed at birth. Among them, 37 of the mothers had their IgM+ status confirmed by ELISA or neutralization assay. **‡Column percentages shown.**

§Italicized outcomes are subsets of their larger category. Numbers, percentages, and p values are shown for each outcome and category, if applicable.

584 ¶Among the three study infants with multiple congenital anomalies, one also had cleft lip/palate, asymmetric microcephaly,

585 craniocynostosis, hypotonia, and died on day 2; another also had loss of consciousness, seizures, hypotonia, and sustained microcephaly through 6 months; another was a stillbirth with facial dysmorphia.

#Study infants that fell under multiple abnormal categories were only counted once under "Any abnormality."

588